Publication
Ireland
On 31 October 2023, the Screening of Third Country Transactions Act 2023 (the “Act”), which establishes a new foreign direct investment ("FDI") screening regime in Ireland, was enacted.
Canada | Publication | October 2023
Norton Rose Fulbright lawyers Kristin Wall, Randy Sutton, Veronique Barry, Christopher Guerreiro and Sarah Pennington contributed the Canada chapters to the Practical Law Life Sciences Global Guide on commercialization and regulation. The Guide is published in a Q&A format by Thomson Reuters, which is a leading global platform for trusted, up-to-date legal know how across all major practice areas.
Life Sciences Commercialisation in Canada: Overview
The Q&A Guide to life sciences commercialisation in Canada provides an overview of Canada’s life sciences sector, pricing and state funding, distribution and sale, importing, advertising, patents, trade marks, competition law, and product liability.
Life Sciences Regulation in Canada: Overview
The Q&A guide to life sciences regulation in Canada reviews the main legislation governing pharmaceuticals in Canada. The guide provides an overview of key practical issues, including clinical trials, manufacturing, marketing, abridged procedures, pharmacovigilance, data privacy, packaging and labelling, biological medicines, medical devices, health care IT, combination products, and natural health products.
Publication
On 31 October 2023, the Screening of Third Country Transactions Act 2023 (the “Act”), which establishes a new foreign direct investment ("FDI") screening regime in Ireland, was enacted.
Publication
On 01 August 2024, the European Commission (EC) launched a public consultation on the draft text of the Guidelines on the application of Article 102 TFEU to abusive exclusionary conduct by dominant undertakings (the draft Guidelines).
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023